Recurrent Membranoproliferative Glomerulonephritis After Kidney Transplantation: Risk Factors and Impact on Graft Survival.
Journal
Annals of transplantation
ISSN: 2329-0358
Titre abrégé: Ann Transplant
Pays: United States
ID NLM: 9802544
Informations de publication
Date de publication:
18 Jul 2023
18 Jul 2023
Historique:
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
18
7
2023
Statut:
epublish
Résumé
BACKGROUND Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of end-stage renal disease (ESRD). Recurrence rates after transplantation range from 11.8% to 18.9% after 5 and 15 years, respectively. This study aimed to assess the risk factors of MPGN recurrence after kidney transplantation and its impact on graft survival. MATERIAL AND METHODS This was a single-center retrospective cohort, including renal transplant recipients older than 18 years, with a diagnosis of MPGN in native kidneys. Data were obtained from medical records during the first 5-year post-transplant follow-up. Primary endpoints were graft function and survival. Secondary endpoints were MPGN recurrence risk factors and these cases' clinical, laboratory, and histological features. RESULTS Twenty-eight patients were included; the majority male (60.7%), with a mean age of 24.0±9.4 years. At MPGN native diagnosis, all patients presented proteinuria, with C3 consumption in 42.9%. Histological analysis showed 13 (42.9%) MPGN type I and 5 (17.9%) type II, with no cases of type III. MPGN recurrence occurred in 7 (25.0%) patients; 85.7% were male, 57.1% were recipients from a living donor, all presenting nephrotic syndrome and hematuria, with C3 consumption in 71.4%. The graft function was similar between the groups. Two (28.6%) patients progressed to graft failure in the recurrence group, and 1 died with a functioning graft. CONCLUSIONS The MPGN recurrence rate was 25%, most of them recipients of kidneys from living donors. Nephrotic syndrome and C3 consumption were frequent at recurrence. The graft function was similar between the groups, and the 5-year graft survival rate in the recurrence group was higher than in other studies.
Identifiants
pubmed: 37461201
pii: 940502
doi: 10.12659/AOT.940502
pmc: PMC10362803
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e940502Références
N Engl J Med. 2012 Mar 22;366(12):1119-31
pubmed: 22435371
J Nephrol. 2022 Sep;35(7):1801-1808
pubmed: 35441256
Clin Nephrol. 2023 Feb;99(2):69-77
pubmed: 36519938
Kidney Int. 2010 Apr;77(8):721-8
pubmed: 20130531
Int J Mol Sci. 2020 Aug 19;21(17):
pubmed: 32824988
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Curr Opin Organ Transplant. 2021 Aug 1;26(4):360-380
pubmed: 34039882
Transplant Proc. 2008 Apr;40(3):746-8
pubmed: 18455005
Am J Transplant. 2014 Feb;14(2):272-83
pubmed: 24472190
Kidney Int. 2017 Aug;92(2):461-469
pubmed: 28601198
Front Immunol. 2019 Aug 14;10:1944
pubmed: 31475005
Transplant Rev (Orlando). 2013 Oct;27(4):126-34
pubmed: 23954034
Hum Pathol. 2016 Jan;47(1):115-20
pubmed: 26547252